Literature DB >> 14506059

In vitro interaction of flucytosine with conventional and new antifungals against Cryptococcus neoformans clinical isolates.

Patrick Schwarz1, Françoise Dromer, Olivier Lortholary, Eric Dannaoui.   

Abstract

Combinations of flucytosine with conventional and new antifungals were evaluated in vitro against 30 clinical isolates of Cryptococcus neoformans. Synergy determined by checkerboard analysis was observed with combinations of fluconazole, itraconazole, voriconazole, amphotericin B, and caspofungin with flucytosine against 77, 60, 80, 77, and 67% of the isolates, respectively. Antagonism was never observed. Killing curves showed indifferent interactions between triazoles and flucytosine and synergy between amphotericin B and flucytosine.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14506059      PMCID： PMC201138          DOI： 10.1128/AAC.47.10.3361-3364.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  23 in total

1.  The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000.

Authors:  Sara A Mirza; Maureen Phelan; David Rimland; Edward Graviss; Richard Hamill; Mary E Brandt; Tracie Gardner; Matthew Sattah; Gabriel Ponce de Leon; Wendy Baughman; Rana A Hajjeh
Journal:  Clin Infect Dis       Date:  2003-02-27       Impact factor: 9.079

2.  Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice.

Authors:  A Polak
Journal:  Chemotherapy       Date:  1987       Impact factor: 2.544

3.  Evaluation of amphotericin B and flucytosine in combination against Candida albicans and Cryptococcus neoformans using time-kill methodology.

Authors:  D J Keele; V C DeLallo; R E Lewis; E J Ernst; M E Klepser
Journal:  Diagn Microbiol Infect Dis       Date:  2001-11       Impact factor: 2.803

4.  In-vitro interactions of itraconazole with flucytosine against clinical isolates of Cryptococcus neoformans.

Authors:  F Barchiesi; D Gallo; F Caselli; L F Di Francesco; D Arzeni; A Giacometti; G Scalise
Journal:  J Antimicrob Chemother       Date:  1999-07       Impact factor: 5.790

5.  A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis.

Authors:  J E Bennett; W E Dismukes; R J Duma; G Medoff; M A Sande; H Gallis; J Leonard; B T Fields; M Bradshaw; H Haywood; Z A McGee; T R Cate; C G Cobbs; J F Warner; D W Alling
Journal:  N Engl J Med       Date:  1979-07-19       Impact factor: 91.245

6.  In vitro susceptibility studies of Cryptococcus neoformans isolated from patients with no clinical response to amphotericin B therapy.

Authors:  L Rodero; S Córdoba; P Cahn; F Hochenfellner; G Davel; C Canteros; S Kaufman; L Guelfand
Journal:  J Antimicrob Chemother       Date:  2000-02       Impact factor: 5.790

7.  Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.

Authors:  Julie A Stone; Sherry D Holland; Peter J Wickersham; Andrew Sterrett; Michael Schwartz; Cynthia Bonfiglio; Michael Hesney; Gregory A Winchell; Paul J Deutsch; Howard Greenberg; Thomas L Hunt; Scott A Waldman
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

8.  Interactions among amphotericin B, 5-fluorocytosine, ketoconazole, and miconazole against pathogenic fungi in vitro.

Authors:  F C Odds
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

9.  Combination therapy of experimental candidiasis, cryptococcosis and aspergillosis in mice.

Authors:  A Polak; H J Scholer; M Wall
Journal:  Chemotherapy       Date:  1982       Impact factor: 2.544

10.  In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans.

Authors:  M H Nguyen; F Barchiesi; D A McGough; V L Yu; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191
View more
  19 in total

1.  Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.

Authors:  Patrick Schwarz; Guilhem Janbon; Françoise Dromer; Olivier Lortholary; Eric Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2006-10-16       Impact factor: 5.191

2.  Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis.

Authors:  Patrick Schwarz; Françoise Dromer; Olivier Lortholary; Eric Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

3.  Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis.

Authors:  E Dannaoui; M Abdul; M Arpin; A Michel-Nguyen; M A Piens; A Favel; O Lortholary; F Dromer
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

4.  Intracranial aspergillosis involving the internal auditory canal and inner ear in an immunocompetent patient.

Authors:  Y-S Cho; D K Lee; S D Hong; W S Oh
Journal:  AJNR Am J Neuroradiol       Date:  2007-01       Impact factor: 3.825

5.  In vitro antifungal combination of flucytosine with amphotericin B, voriconazole, or micafungin against Candida auris shows no antagonism.

Authors:  A L Bidaud; F Botterel; A Chowdhary; E Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2019-10-07       Impact factor: 5.191

6.  In vitro interactions of micafungin with other antifungal drugs against clinical isolates of four species of Cryptococcus.

Authors:  Carolina Serena; Belkys Fernández-Torres; F Javier Pastor; Luciana Trilles; Márcia Dos Santos Lazéra; Nicole Nolard; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

Review 7.  Cryptococcosis: epidemiology, fungal resistance, and new alternatives for treatment.

Authors:  F P Gullo; S A Rossi; J de C O Sardi; V L I Teodoro; M J S Mendes-Giannini; A M Fusco-Almeida
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-07-04       Impact factor: 3.267

8.  In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus.

Authors:  Eric Dannaoui; Olivier Lortholary; Françoise Dromer
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

9.  Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study.

Authors:  Françoise Dromer; Simone Mathoulin-Pélissier; Odile Launay; Olivier Lortholary
Journal:  PLoS Med       Date:  2007-02       Impact factor: 11.069

Review 10.  Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal.

Authors:  Angela Loyse; Françoise Dromer; Jeremy Day; Olivier Lortholary; Thomas S Harrison
Journal:  J Antimicrob Chemother       Date:  2013-06-20       Impact factor: 5.790
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.